Home/Filings/4/0000899243-17-005803
4//SEC Filing

CoLucid Pharmaceuticals, Inc. 4

Accession 0000899243-17-005803

CIK 0001348649operating

Filed

Feb 28, 7:00 PM ET

Accepted

Mar 1, 5:02 PM ET

Size

7.3 KB

Accession

0000899243-17-005803

Insider Transaction Report

Form 4
Period: 2017-03-01
Transactions
  • Other

    Common Stock, par value $0.001

    2017-03-01$46.50/sh+19,285,108$896,757,522100 total
Transactions
  • Other

    Common Stock, par value $0.001

    2017-03-01$46.50/sh+19,285,108$896,757,522100 total
Footnotes (1)
  • [F1]On March 1, 2017, Eli Lilly and Company ("Parent") and ProCar Acquisition Corporation ("Merger Sub") completed the transactions contemplated by the Agreement and Plan of Merger, dated as of January 17, 2017, by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Parent and Merger Sub (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly-owned subsidiary of Parent (the "Surviving Corporation"). At the effective time of the Merger, the outstanding shares of common stock of Merger Sub were converted into and became shares of the Surviving Corporation.

Issuer

CoLucid Pharmaceuticals, Inc.

CIK 0001348649

Entity typeoperating

Related Parties

1
  • filerCIK 0001348649

Filing Metadata

Form type
4
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 5:02 PM ET
Size
7.3 KB